BestCo announced that it is the new name for BestSweet, a manufacturer, developer and marketer of consumer healthcare products for retailers and marketers of over-the-counter drug products and dietary supplements. According to a release, BestCo has evolved to become a supplier of cough drops, throat drops, soft chews, coated chews and other...
Actavis, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing Actavis' New Drug Application for a progestin-only transdermal contraceptive patch for use by women to prevent pregnancy. Actavis' progestin-only patch is designed to provide continuous delivery of norethindrone to the systemic circulation during a...
By a News Reporter-Staff News Editor at Pharma Business Week- Prasco Laboratories announced it has signed an exclusive distribution and supply agreement with WellSpring Pharmaceutical Corp. for Phenoxybenzamine Hydrochloride Capsules, USP. As part of the agreement, Prasco, LLC is prepared to immediately market the authorized generic of DIBENZYLIN
MOUNTAIN VIEW, Calif., May 13, 2013 VIVUS, Inc. today mailed a letter to stockholders providing an update on the Company's recent progress. Over the past seven months since the launch of Qsymia, VIVUS has successfully built the commercial foundation for the medical obesity treatment category and the Qsymia brand. Just this month, the American Ass
Novartis announced today that the US Food and Drug Administration has approved Ilaris for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older. Study 1 showed that 84% of patients treated with one subcutaneous dose of Ilaris achieved the primary endpoint of the adapted pediatric American College of...
You should read the following Management's Discussion and Analysis of Financial Condition and Results of Operations together with our unaudited condensed consolidated financial statements and the related notes included in "Part I-Item 1. Financial Statements" of this Quarterly Report on Form 10- Q and the condensed consolidated financial statements
Our MD&A is provided in addition to the accompanying condensed consolidated financial statements and footnotes to assist readers in understanding Pfizer's results of operations, financial condition and cash flows. The MD&A is organized as follows:? Overview of Our Performance, Operating Environment, Strategy and Outlook. section, beginning on pag
Actavis today confirmed that the United States District Court for the Southern District of Florida has found United States Patent No. 6,773,720 valid and infringed by Actavis' generic version of Shire's Lialda . Actavis is reviewing the court's decision and will evaluate all available options, including an appeal. Actavis' Abbreviated New Drug...
Actavis, Inc. today confirmed that the United States District Court for the Southern District of Florida has found United States Patent No. 6,773,720 valid and infringed by Actavis' generic version of Shire's Lialda . Actavis' Abbreviated New Drug Application for its generic version of Lialda is currently pending with the U.S. Food and Drug...
We are a pharmaceutical services company serving the United States, Canada and select global markets. We are committed to a plan to divest AndersonBrecon and in March 2013, we committed to a plan to divest AmerisourceBergen Canada Corporation; therefore, their operations are classified as discontinued operations for all periods presented.
BestCo announced that it is the new name for BestSweet, a manufacturer, developer and marketer of consumer healthcare products for retailers and marketers of over-the-counter drug products and dietary supplements. According to a release, BestCo has evolved to become a supplier of cough drops, throat drops, soft chews, coated chews and other...
Paladin Labs Inc., a leading specialty pharmaceutical company, today reported its financial results for the quarter ended March 31, 2013. Announced that all closing conditions had been fulfilled relating to the acquisition of a controlling stake of 50.01% in Ativa Pharma S.A. effective January 1, 2013 Obtained approval from the Toronto Stock Ex
You should review carefully the factors identified in "Risk Factors" in this report in Part II, Item 1 A. and in Part I, Item 1 A. in our most recent Annual Report on Form 10- K filed with the SEC. The three months ended March 31, 2013 are also referred to as the second quarter of fiscal 2013. 20. NUEDEXTA, 20/ 10 mg, is approved in the United Stat
The patents that provided market exclusivity for Singulair in a number of major European markets expired in February 2013. In addition, the patent that provided U.S. market exclusivity for Maxalt expired in December 2012 and the Company lost U.S. market exclusivity for Propecia in January 2013. In March 2013, the Company announced the appointment o
OPKO Health, Inc., a multi-national biopharmaceutical and diagnostics company, today reported operating and financial highlights for the first quarter of 2013.. Consistent with our growth strategy, progress across most business fronts accelerated during the first quarter of 2013,? said Phillip Frost, OPKO s Chairman and Chief Executive Offi
Paladin Labs Inc., a leading specialty pharmaceutical company, today reported its financial results for the quarter ended March 31, 2013. Issued a combined balance of $4.2 million secured loans to two pharmaceutical companies Launched Amniosense (TM), Canada's first OTC amniotic fluid leak detection test Launched Silenor (R) for the treatment
The following discussion should be read in conjunction with our condensed consolidated financial statements and other financial information appearing elsewhere in this quarterly report. In addition to historical information, the following discussion and other parts of this quarterly report contain forward-looking statements.
Up until the fall of 2005, Molecular USA was in the business of mineral exploration and development of a mineral property. On October 13, 2005, Molecular USA entered into a distribution and supply agreement with Molecular Pharmacology Pty. Under the terms of the distribution and supply agreement, Molecular USA received the exclusive distribution ri
The Pew Charitable Trusts today applauded Senators Kirsten Gillibrand, Dianne Feinstein, and Susan Collins, for introducing the Antimicrobial Data Collection Act, which would require the U.S. Food and Drug Administration, or FDA, to report more information on the annual sales of antibiotics used among industrial farm animals. The bill introduced by
Actavis, Inc., a leading specialty pharmaceutical company, announced today that Paul Bisaro, Actavis' President and Chief Executive Officer, will provide an overview and update of the Company's business at the Bank of America Merrill Lynch 2013 Health Care Conference on Tuesday, May 14, 2013 at 8:40 AM Pacific Time at the Encore at the Wynn in Las
This financial review presents our operating results for the three month periods ended March 31, 2013 and 2012, and our financial condition at March 31, 2013. The following review should be read in connection with the information presented in our unaudited condensed consolidated financial statements and related notes for the three month period ende
FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company. Sildenafil is the active ingredient in an FDA- approved drug used for the treatment of male Erectile Dysfunction, making Ligh
Q: I can't stay on schedule with my high blood pressure meds. $177 billion annually in avoidable hospitalizations and other health care costs. Cost matters: 23 percent of uninsured people ages 18 to 64 skip their medicine to reduce costs; 14 percent on Medicaid do, as do 9 percent of those with private insurance.
Perrigo Company traces its history back to 1887. What was started as a small local proprietor selling medicinals to regional grocers has evolved into a leading global pharmaceutical company that manufactures and distributes more than 45 billion oral solid doses and more than two billion liquid doses, as well as dozens of other product forms, each y
MOUNTAIN VIEW, Calif., May 7, 2013 VIVUS, Inc. today announced that Richard Fante, former president U.S., CEO North America and regional vice president Americas at AstraZeneca, has agreed to provide advisory services to the Company. "We are excited to have an executive of Richard Fante's caliber advising VIVUS at this critical time," commented L
